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Antiplatelet resistance is emerging as a signiﬁcant factor in effective secondary stroke pre-
vention. Prevalence of aspirin and clopidogrel resistance is dependent upon laboratory test
and remains contentious. Large studies in cardiovascular disease populations have demon-
strated worse ischemic outcomes in patients with antiplatelet resistance, particularly in
patients with coronary stents. Thromboembolism is a complication of neurointerventional
procedures that leads to stroke. Stroke rates related to aneurysm coiling range from 2 to
10% and may be higher when considering silent ischemia. Stroke associated with carotid
stenting is a major cause of morbidity. Antiplatelet use in the periprocedure setting varies
among different centers. No guidelines exist for use of antiplatelet regimens in neuroin-
terventional procedures. Incidence of stroke in patients post procedure may be partly
explained by resistance to antiplatelet agents. Further research is required to establish the
incidence of stroke in patients with antiplatelet resistance undergoing neurointerventional
procedures.
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INTRODUCTION
The clinical signiﬁcance of aspirin and clopidogrel resistance
is becoming increasingly recognized. Recent large studies have
established prevalence in healthy, as well as cardiovascular popula-
tions. Prevalence among stroke populations is less well established.
Methods for testing resistance have become cheaper, faster, and
more accessible at the point-of-care, however validity of these tests
remains questionable.
Thromboembolus leading to stroke is a potential complica-
tion of neurointerventional procedures. Aneurysm coil emboliza-
tion, ﬂow diversion stenting, intracranial, and extracranial stent-
ing are associated with low rates thromboembolism that are
further reduced with effective antiplatelet management. Prac-
tice between interventionalists varies between centers with no
established guidelines to guide clinical practice.
The aim of this review was to evaluate incidence of thromboe-
mbolus related toneurointerventional procedures,antiplatelet reg-
imens, and the potential impact of resistance to aspirin and clopi-
dogrel in patients undergoing neurointerventional procedures.
ANTIPLATELET RESISTANCE
Antiplatelet therapy decreases stroke recurrence by 15–20%
(Sandercock et al., 2008). Successful stroke prevention leads to
signiﬁcant reduction in morbidity, mortality, and cost burden to
the healthcare system (Holloway et al., 1999). Antiplatelet therapy
occurs via inhibition of platelet aggregation. Successful aggre-
gation inhibition lowers the risk of arterial occlusion, with a
consequent lower risk of stroke. However, there is emerging evi-
dence that a proportion of the population harbors resistance to
antiplatelet therapy.
ASPIRIN RESISTANCE PATHOPHYSIOLOGY AND LABORATORY
DIAGNOSIS
Aspirin inhibits cyclooxygenase 1 (COX 1) preventing the forma-
tionof thromboxaneA2 (TXA2),a platelet aggregatingprostanoid.
Laboratory resistance is deﬁned as the failure of aspirin to inhibit
platelet thromboxane A2 production or inhibit tests of platelet
function that are dependent on platelet TX production (Hankey
andEikelboom,2006).Multiple assays of platelet function exist but
correlate poorly with regard to positive predictive value. Applica-
tion of the assays in a single population resulted in a variance of
diagnosis of aspirin resistance between 4 and 60% (Lordkipanidzé
et al., 2007). The lack of a reproducible, cheap, and accurate test
has hampered clinical utility.
The gold standard test is considered to be light transmittance
aggregometry (LTA; Harrison, 2005). This test utilizes light trans-
mittance across plasma during platelet aggregation in response
to different agonists (ADP, collagen, arachidonic acid). The test
is costly, time consuming, operator dependent, and suffers poor
reproducibility (Nicholson et al., 1998). One group of tests aims
to measure end products of the TX A2 pathway such as serum TX
B2 (Hart et al., 2003) and urine 11-dehydroTX B2 (Eikelboom
et al., 2002). These metabolites may better reﬂect the amount
of TX A2 derived from sources other than platelets, such as
macrophages and monocytes (Mansour et al., 2009). The platelet
function analyzer PFA-100 (Dade Behring, Liederbach, Germany)
is a point-of-care test that times the formation of a platelet plug in
an artiﬁcial artery. Aspirin resistance is deﬁned as a closure time
<164 s despite regular aspirin intake. It is fast and reproducible but
expensive, and has failed to demonstrate correlation with clinical
outcome (Christiaens et al., 2008). A promising point-of-care test
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is the VerifyNow-Aspirin (Ultegra Rapid Platelet Function Assay,
Accumetrics Inc., San Diego, CA,USA).With a cut off value at 550
aspirin reaction units (ARU), the test correlates well with the gold
standard LTA, showing good speciﬁcity with highly reproducible
results (Nielsen et al., 2008).
ASPIRIN RESISTANCE: CLINICAL IMPLICATIONS
Prevalence of aspirin resistance within the population appears
to be between 6 and 27% (Hovens et al., 2007; Mansour et al.,
2009; Shen et al., 2009). The range in prevalence between studies
reﬂects several factors, including use of test. The largest meta-
analysis that included 42 studies detected a mean prevalence of
24% [95% conﬁdence interval (CI) 20–28%; Hovens et al., 2007].
When the gold standard LTA was used however, the rate dropped
to 6% (95% CI 0–12%). Use of the point-of-care platelet ana-
lyzer detected a prevalence of 26% (95% CI 21–31%), suggesting
that the method of deﬁning aspirin resistance strongly inﬂu-
ences estimated prevalence. Interestingly, resistance was shown
to be higher in low dose (≤100mg) vs. high dose (≥300mg)
populations: [36% (95% CI 28–43%) vs. 19% (95% CI 11–
26%), P = 0.0001] suggesting a signiﬁcant dose effect on rates of
resistance.
A meta-analysis of a cardiovascular disease population
(n = 2930) reported a prevalence of 28% of aspirin resistance
that was signiﬁcantly associated with an increased future risk of
ischemic events (Krasopoulos et al., 2008). Other signiﬁcant clin-
ical associations with aspirin resistance in this type of population
have recently been reported as including older age, hypertension,
and hyperlipidemia (Beigel et al., 2011).
Similar rates of aspirin resistance in stroke populations have
been reported. Harrison et al. (2005) compared prevalence in a
population of 100 patients receiving aspirin after TIA or stroke.
Prevalence varied depending on test used, with rates of 22%
using the PFA-100, 17% using the RPFA, and only 5% using
LTA (Harrison et al., 2005). Agreement between the tests was
poor. Agreement between the RPFA and LTA (κ= 0.16, 95% CI
0.08–0.39, P = 0.11), PFA-100 and LTA (κ= 0.09, 95% CI 0.12–
0.30, P = 0.32) and between the two point-of-care tests (κ= 0.14,
95% CI 0.08–0.36, P= 0.15) were poor. Only 2% of patients were
aspirin non-responders by all three tests. We previously demon-
strated in a stroke population (n = 50) that aspirin resistance
appeared to occur at a rate of 30% (Bennett et al., 2008) using
the RPFA. This may reﬂect a higher rate of aspirin resistance
in stroke populations compared to healthy populations (Alberts,
2010). The RPFA point-of-care test was recently used in a larger
trial of 106 patients. Aspirin resistance in this group recruited
at onset of acute stroke was detected in 33% and was associ-
ated with increased short and long term mortality (Ozben et al.,
2011).
Poor agreement between tests for aspirin resistance has a sig-
niﬁcant effect on estimated prevalence rates. Other factors that
affect prevalence appear to include aspirin dose and comorbidi-
ties. Despite this, lessons from cardiovascular population studies
suggest that presence of resistance does signiﬁcantly predict mor-
bidity in those populations. Large prospective studies are required
to demonstrate this in stroke populations. Early evidence suggests
that aspirin resistance may be higher in stroke populations.
CLOPIDOGREL RESISTANCE PATHOPHYSIOLOGY AND LABORATORY
DIAGNOSIS
Clopidogrel, a commonly administered antiplatelet, achieves
aggregation inhibition by binding to the ADP receptor (P2Y12)
expressed on the platelet membrane (Gurbel et al., 2003;
O’Donoghue et al., 2009). Clopidogrel is a prodrug ingested in
its inactive form, requiring conversion to active form by CYP2C19
superfamily of drug metabolizers (Mega et al., 2009). It exerts its
action via active metabolites, which rise proportionally to increas-
ing dose, between 75 and 150mg (Caplain et al., 1999). A tapering
and ceiling effect on platelet aggregation inhibition appears to
occur above doses of 400–600mg (Farid et al., 2010). In vivo stud-
ies demonstrate that the conversion to active metabolites requires
liver microsomes and NADPH in the presence of a reducing agent
(glutathione; Savi et al., 2000). The ﬁve CYP forms contribut-
ing to formation of active metabolites include CYP3A, CYP2B6,
CYP1A2,CYP2C19, andCYP2C9 (Kazui et al., 2010). Only 10%of
the clopidogrel dose is converted into active metabolite (Hagihara
et al., 2009).
A hypofunctioning form of CYP2C19 leads to subtherapeu-
tic levels of active clopidogrel (Mega et al., 2009). It has been
shown that differing forms of CYP2C19 may account for up to
12% of clopidogrel “failures” (Shuldiner et al., 2009). In addition,
different alleles of the CYP2C19 gene have been identiﬁed and
their impact on clopidogrel activity further elucidated as: ∗1 (nor-
mal metabolizer), ∗2 (hypometabolizer), ∗3 (hypometabolizer),
and ∗17 (hypermetabolizer; Maeda et al., 2011). Carriers of the
CYP2C19∗2 will exhibit subtherapeutic levels of the active form of
clopidogrel due to reduced metabolism of clopidogrel. Of interest,
there appears to be a genetic dose effect whereby carriers of ∗2/∗2
(homozygous hypometabolizer) exhibit poorer platelet inhibition
compared to carriers of ∗2/∗1 (heterozygous hypometabolizer;
Maeda et al., 2011).
The potential clinical sequela of CYP2C19∗2 carriers is failure
in platelet inhibition and signiﬁcantly increased risks of cardio-
vascular events and death (Mega et al., 2009). This led to a recent
recommendation from FDA in March 2010 requiring physicians
to consider alternative antiplatelet therapy to carriers of CYP2C19
non-functioning allele (e.g., CYP2C19∗2). Particularly relevant is
the ﬁnding that CYP2C19∗2 (hypometabolizer) and ∗3 (hypome-
tabolizer) allelic frequencies are 30 and 6.8%, respectively in Asian
patients (Hwang et al., 2011).
Similar to aspirin, methods for diagnosis of clopidogrel resis-
tance are variable however the tests appear to be in better agree-
ment. The gold standard remains LTA. The turbidimetric method
employs two-channel aggregometer (Chrono-Log 490 Model,
Chrono-Log). Platelet aggregation is assessed within 2 h of sam-
pling using light transmission. A percent inhibition of aggregation
is obtained from calibration by light transmission of platelet rich
plasma and platelet poor plasma. A suboptimal or low response to
a clopidogrel loading dose was deﬁned when inhibition of 6 AM
ADP-induced aggregation 24 h after clopidogrel administration
was<40%. Similarly, a normal inhibitory responsewas considered
when inhibition of ADP- induced platelet aggregation achieved
>40% 24 h after treatment (Angiolillo et al., 2005). This test was
applied in a group of 48 patients undergoing coronary stent-
ing with clopidogrel loading. Forty-eight percent of this group
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were found to have poor platelet aggregation (low responders)
in response to clopidogrel loading. Other groups have reported
varying rates of resistance using turbidometry in patients post
coronary stenting that is at least partly due to varying deﬁnitions of
resistance. Lau (2004) demonstrated 22% resistance in 32 patients
deﬁning resistance as platelet aggregation inhibition<10% follow-
ingADP 20μmol/L. Gori et al. (2008) demonstrated lower rates of
6% using a maximum aggregation rate of >70% following ADP
10μmol/L. This group also looked at dual non-responsiveness
(aspirin and clopidogrel) and demonstrated rates of 6% in their
population of 746 patients. Dual non-responsiveness was an inde-
pendent predictor of drug eluting stent thrombosis [hazard ratio,
(HR): 3.18, 95% CI: 1.14–8.83, P = 0.027].
TheVerifyNow P2Y12 (Accumetrics Inc., San Diego, CA, USA)
is a bedside test that measures the effects of clopidogrel on the
P2Y12 receptor. It utilizes a cartridge-based assay to measure
platelet function rapidly. Results are expressed as P2Y12 reac-
tion units (PRU) reﬂecting amount of P2Y12 receptor-mediated
aggregation. Percent inhibition is calculated as [(1−PRU/baseline
PRU)× 100] reﬂecting a percent change from baseline aggrega-
tion. The estimated baseline result is an independentmeasurement
based on rate and extent of platelet aggregation in the thrombin
receptor-activating peptide channel (Malinin et al., 2006), and has
been evaluated in several studies (Malinin et al., 2007; Jakubowski
et al., 2008). A validation of theVerifyNow P2Y12 assay against the
gold standard LTA was conducted in a population of 591 patients.
The results indicated that the P2Y12 assay andLTAdetected similar
patterns of responses to clopidogrel in patients with cardiovascu-
lar disease and healthy volunteers. The P2Y12 assay was relatively
less sensitive to low and high levels of inhibition but the overall
the results were well correlated (r ∼ 0.7; Jakubowski et al., 2010).
CLOPIDOGREL RESISTANCE: CLINICAL IMPLICATIONS
Several recent large studies have attempted to correlate genetic
variants in CYP genes and cardiovascular outcomes in patients
treated with clopidogrel. Three large studies have demonstrated
a signiﬁcant effect of loss-of-function allele and worse cardiovas-
cular outcomes on clopidogrel. Mega et al. (2009) reported that
in carriers of at least one CYP2C19 reduced-function allele had a
signiﬁcantly reduced maximal platelet aggregation response of 9%
points (using LTA in response to 20μmol/L of ADP) when com-
pared to non-carriers. Carriers had a signiﬁcantly increased rate
of composite outcome (myocardial infarction, stroke, or related
death) compared with non-carriers (12.1 vs. 8.0%; HR for carri-
ers, 1.53; 95%CI, 1.07–2.19;P = 0.01). The increase in risk of stent
thrombosiswasmuchhigher for carriers compared tonon-carriers
(2.6 vs. 0.8%; HR, 3.09; 95% CI, 1.19–8.00; P = 0.02). Collet et al.
(2009) investigated a populationof 259 youngpatients (<45 years)
using similar outcomes. Loss-of-function carriers taking clopido-
grel suffered the composite cardiovascular outcome more often
than in non-carriers [15 vs. 11 events;HR3·69 (95%CI 1.69–8.05),
P = 0.0005]. Again, stent thrombosis was shown to be a greater
risk in carrier populations [eight vs. four events; HR 6·02 (1·81–
20·04), P = 0.0009]. Shuldiner et al. (2009) reported an increased
risk of cardiovascular ischemic event or death in patients with a
loss-of-function allele (20.9 vs. 10.0%,HR2.42; 95%CI,1.18–4.99;
P = 0.02). The loss-of-function allele (CYP2C19∗2)was associated
with diminished clopidogrel response, accounting for 12% of the
variation in LTA platelet aggregation to ADP (P = 4.3× 10−11).
These results were not repeated in a large trial by Paré et al. (2010)
involving 5059 patients. The effect of clopidogrel in reducing the
rate of cardiovascular events was similar in patients with carriers
for loss-of-function alleles and non-carriers [rate among carriers,
8.0% with clopidogrel vs. 11.6% with placebo; HR with clopi-
dogrel, 0.69; 95% CI, 0.49–0.98; rate among non-carriers, 9.5 vs.
13.0%; HR, 0.72; 95% CI, 0.59–0.87]. The authors suggested the
divergent ﬁnding was due to differences in rates of coronary stent-
ing. Rates of stenting were 14.5% in this population compared to
70% in the three positive trials (Collet et al., 2009; Mega et al.,
2009; Shuldiner et al., 2009). They concluded that the greatest use
of clopidogrel was in the reduction in the rate of stent thrombosis.
Evidence from large myocardial infarction trials have demon-
strated the clinical beneﬁt of addition of clopidogrel to aspirin
in achieving superior antiplatelet activity (COMMIT Collabora-
tive Group, 2005; Sabatine et al., 2005; L’Allier et al., 2008). The
COMMIT trial of 45,852 patients with acutemyocardial infarction
investigated the beneﬁt of the addition of clopidogrel to aspirin
in patients within 24 h of onset. Composite primary outcome of
death, reinfarction or stroke at discharge was signiﬁcantly reduced
in patients on combination antiplatelet therapy (9.2 vs. 10.1%
P = 0.002; COMMIT Collaborative Group, 2005). The CLARITY-
TIMI investigated the beneﬁt of addition of clopidogrel to aspirin
within 12 h of onset of ST elevation myocardial infarction in 3491
patients. Primary composite endpoint of occluded infarct related
artery on angiography or death was signiﬁcantly reduced in the
combination antiplatelet agent group 15 vs. 21.7% P < 0.001;
Sabatine et al., 2005).Authors concluded that the additionof clopi-
dogrel to aspirin improves the patency rate of the infarct related
artery and reduces ischemic related complications.
There is scant evidence of the effect of clopidogrel resistance in
stroke populations and greater risk for recurrent stroke. Lessons
are drawn from large cardiovascular trials that include stroke in
composite cardiovascular outcomes. It is likely that clopidogrel
resistance exists in stroke populations as it does in the general
population (Fukuoka et al., 2011), if not at higher rates. Evidence
that resistance is associated with an increased risk for recurrent
stroke remains to be seen.
THROMBOEMBOLIC COMPLICATIONS OF
NEUROINTERVENTIONAL PROCEDURES
ANEURYSM COIL EMBOLIZATION
Procedure related mortality in endovascular treatment of unrup-
tured aneurysm is around 0.5% (Lanterna et al., 2004). The most
feared and major complication related to mortality is aneurysm
rupture and hemorrhage, however the most common compli-
cation is thromboembolism leading to stroke (Lanterna et al.,
2004). This appears signiﬁcantly more associated with coiling than
clipping (Gerlach et al., 2007).Development of local thrombus for-
mation may involve protrusion of coil loops into the parent artery
(Yamada et al., 2007). Thrombus associated with balloon assisted
coiling (BAC) relates to stasis associatedwith balloon inﬂation and
presence of foreign body.
Lanterna et al. (2004) reported a systematic literature review of
elective aneurysm embolization complications between 1990 and
www.frontiersin.org December 2011 | Volume 2 | Article 83 | 3
Oxley et al. Antiplatelet resistance in neurointervention
2002. Permanent morbidity rates were reported in 794 patients.
When all morbidities were considered, 80% were due to stroke
secondary to thromboembolism. By comparison only 7.5% were
due to hemorrhage. Morbidity decreased from 8.6 to 4.5% when
the average calendar year of treatment was 1995 or later, suggest-
ing an improving technique over time. The authors concluded
that prevention and treatment of thromboembolism may be the
most effective way to improve clinical outcome with aneurysm
embolization.
Other studies have reported rates of thromboembolism in coil-
ing of unruptured aneurysms, ranging from 1.3 to 9.2% (van
Rooij and Sluzewski, 2006; Gerlach et al., 2007; Layton et al., 2007;
Yamada et al., 2007; Brooks et al., 2008; Im et al., 2008). The rate
of actual infarction is likely higher due to undetected silent infarc-
tion. Brooks et al. (2008) demonstrated the rate of stroke during
coiling increased to 25% when using diffusion restriction on MRI
DWI routinely post procedure.
No clinical guidelines exist for the management of antico-
agulation and antiplatelet agent choice in neurointerventional
procedures. According to recommendations (assembled from lit-
erature review and survey of expert opinion in 2007) from the
World Federation of Interventional and Therapeutic Neuroradi-
ology (WFITN) reduction of thrombotic complication in narrow
neck aneurysm is managed by use of heparin intra-procedurally
(see Table 1).
Balloon assisted coil embolization (BACE) was described in
1997 as a safe technique for treatment of wide necked aneurysms
(Moret et al., 1997). WFITN recommendations include use of
aspirin post procedure in this group, but not with pre-procedure
loading dose. This remains an area of contention, with use of an
antiplatelet loading regimen being center dependent.
Two groups have reported retrospective analyses reviewing
thromboembolic complications in aneurysms treated with BAC.
One of these groups used pre-procedure antiplatelet loading and
the other did not. Sluzewski et al. (2006) compared rates of
thromboembolism in aneurysms treated with BACE compared
to standard coiling embolization. Both groups were given heparin
during the procedure and for 48 h post procedure. Aspirin was
used for 3months post procedure. The mean aneurysm diameter
in the BACE group was signiﬁcantly wider than the standard coil-
ing group (11.7 vs. 8.3mm P < 0.0001). 9.8% in the BACE group
(n = 71) had symptomatic thromboembolism (causing death or
disability) compared with 2.2% in the standard coiling emboliza-
tion group (n = 756, P < 0.0001). Layton et al. (2007) report a
non-signiﬁcant difference in thromboembolus risk in 73 patients
treated with BACE vs. 148 patients without balloon assistance (14
vs. 9% P = 0.35), however patients suspected of requiring bal-
loon assistance were treated with loading dual-therapy. It was
unclear whether the two groups had a signiﬁcant difference in
size of aneurysm. Of this total population of 221, 13 (6%) had
symptomatic thromboembolic complications. Twelve of these 13
were not taking pre-procedure antiplatelet medication. None of
the patients on clopidogrel alone or on combination clopidogrel
and aspirin developed thromboembolic complications. The use
of clopidogrel (either alone or combined with aspirin) was the
only preprocedural antiplatelet agent that showed a signiﬁcant dif-
ference in local thrombus formation (P = 0.01) or symptomatic
thromboembolic complication (P = 0.04).
Table 1 | Anticoagulation recommendations for neurointerventional procedures.
Intraprocedural anticoagulation Antiplatelet loading dose Ongoing antiplatelet treatment
Small neck aneurysm coiling Heparin bolus of 5000U, then 1000U/l
continuously during the procedure, with
control of ACT (∼200)
Nil Nil
Wide neck aneurysm coiling Heparin bolus 5000U, then 1000U/l
continuously, with control of ACT ∼200
Nil Aspirin 100mg to be continued
indeﬁnitely
Aneurysm stenting without
additional coiling
Heparin bolus 5000U, then 1000U/l
continuously, with control of ACT ∼200
3days before procedure, aspirin
100mg and clopidogrel 75mg
Dual-therapy depending on stent-model,
with aspirin to be continued indeﬁnitely
thereafter
Aneurysm stenting+ coiling Heparin bolus 5000U, then 1000U/l
continuously, with control of ACT ∼200
3days before procedure, aspirin
100mg and clopidogrel 75mg
Dual-therapy depending on stent-model,
with aspirin to be continued indeﬁnitely
thereafter
Aneurysm
balloon-remodeling
Heparin bolus of 5000U, then 1000U/l
continuously during the procedure, with
control of ACT (∼200)
Nil Nil
Bare metal stent (BMS) Heparin bolus 5000U, then 1000U/l
continuously, with control of ACT ∼200
3days before procedure, aspirin
100mg and clopidogrel 75mg
Dual-therapy for 3months, with aspirin to
be continued indeﬁnitely thereafter
Drug eluting stent (DES) Heparin bolus 5000U, then 1000U/l
continuously, with control of ACT ∼200
3days before procedure, aspirin
100mg and clopidogrel 75mg
Dual-therapy for 1 year, with aspirin to be
continued indeﬁnitely thereafter
Embolization of AVM/DAVF
and tumor
Heparin bolus of 5000U, then 1000U/l
continuously during the procedure, with
control of ACT (∼200)
Nil Nil
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The coiling procedure potentially posing highest risk for
thromboembolism is stent-assisted coiling. This is reﬂected by
standard practice for dual antiplatelet therapy for this group
of patients. A 10-center registry recently published a series of
213 consecutively treated aneurysms using stent-assisted coiling
(Mocco et al., 2011). In this study with mid term follow-up
(median 150 days), nine patients (4%) patients suffered complica-
tions of thrombosis. Twowere in the periprocedural setting during
stent deployment, while seven (3%) were delayed thromboem-
bolism. All seven occurred in the setting of cessation of treatment
of dual antiplatelet therapy. Interestingly none were associated
with coil prolapse into parent vessel.
There is a suggestion that use of an antiplatelet agent prior
to coil embolization (both with and without balloon remodel-
ing) appears to have a protective effect against thromboembolism.
This hypothesis requires investigation in a randomized prospec-
tive trial. The beneﬁt of the antiplatelet agent would need to
outweigh the potential increased risk of bleeding complications
during coiling. BAC of wide necked aneurysm may be associated
with higher rates of thromboembolus and stroke than in narrow
necked aneurysms.
FLOW DIVERTING STENTS
Useof thePipeline (PED,ChestnutMedical,MenloPark,CA,USA)
or Silk (SFD, Balt Extrusion, Montmorency, France) emboliza-
tion device to achieve ﬂow diversion in wide necked aneurysms
(>4mm) with unfavorable dome/neck ratios (<1.5) is becom-
ing widespread. Data is only available from several small trials
with short follow-up periods. The ﬁrst prospective multicenter
trial of 31 patients (Nelson et al., 2011) reported two periproce-
dural strokes (6.4%), however one was due to iatrogenic rupture
of aneurysm and the other likely attributable to regional cover-
age of lenticulostriate branches with multiple PEDs. Patients in
this trial were managed on dual antiplatelet agents with clopido-
grel for a minimum of 30 days and aspirin use for a minimum of
180 days after treatment. Klisch et al. (2011) recently reported two
cases of very late thrombosis (>1 year) of PED constructs in poste-
rior circulation aneurysms. Both patients had clopidogrel ceased
at 12months and presented with symptomatic occlusion within
14 days (Klisch et al., 2011). The authors posited that PEDs may
remain thrombogenic for longer than conventional intracranial
or peripheral bare metal stents and susceptible to very late throm-
bosis. Walcott et al. (2011) recently reported a review of 10 case
series and 190 patients treated with ﬂow diverting stents. Stroke
was reported as a complication in 6%of patients, however perfora-
tor stroke was not able to be distinguished from thromboembolic
stroke. Use of dual antiplatelet agents was adopted bymost groups,
with varying continuation rates. Continuing randomized trials are
needed to address the question of need for, and ideal regimen, of
continuing antiplatelet agents in the setting of insertion of ﬂow
diverting stents.
INTRACRANIAL STENTING
The high risk of stroke related to intracranial arterial stenosis has
been well investigated by theWASID trial (Chimowitz et al., 2005).
The 2-year rates of ischemic stroke were 19.7% in 280 patients
taking 1300mg of aspirin with angiographic grade stenosis of
50–99%. Beneﬁt of self expanding stents over medical therapy
remains to be demonstrated in a randomized controlled clinical
trial. Two recently published papers report outcomes of patients
stented for intracranial stenosis. Fiorella et al. (2011) reported
outcomes in 158 patients from ﬁve centers with 50–99% stenosis
with amean follow-up of 14.2months. Stroke or death occurred in
15.7%,or approximately 13.2%/year. Seventy-six percent occurred
within the ﬁrst 6months and none were recorded after 12months.
Eighty-six percent of the postprocedural events were explained by
antiplatelet interruption or in-stent restenosis. Of the 27.9% that
were complicated by in-stent restenosis, 80.6% of these underwent
target lesion revascularization. Jiang et al. (2011) recently reported
results from a single center prospective Wingspan cohort study.
Patients with >70% intracranial stenosis were treated with a self
expanding stent, and dual antiplatelet therapy for a minimum of
30 days, followed by single agent aspirin (300mg) or clopidogrel
(75mg). The 1-year risk of outcome events was signiﬁcantly lower
than that in similar WASID patients: 7.3% (95% CI, 2.0–12.5%)
vs. 18% (95% CI, 13–24%; P = 0.05). In-stent restenosis rate was
26.7% with a majority undergoing target lesion revascularization.
The Stenting andAggressive Medical Management for Prevent-
ing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial
was recently halted after recruitment of 451 patients due to a 30-
day stroke rate of 14% in the stenting group vs. 5.8% in themedical
arm (National Institute of NeurologicalDisorders and StrokeClin-
ical Alert,April 11, 2011)1. The anticipated 30-day event rate in the
stenting group was 5.2–9.6% based on data presented by Fiorella
et al. (2011) and 10.7% in the medical arm. The event rate in
SAMMPRIS was over double that from the data from Jiang et al.
(2011) and Fiorella et al. (2011).
How are these differing results explained? Stenosis related
hypoperfusion with tendency to orthostatic cerebral ischemia is
less likely to respond to antiplatelet therapy than stenosis caus-
ing artery-to-artery thromboembolus and stroke (Abou-Chebl,
2011). Patients with perforator syndromes due to branch origin
stenosis rather than due to larger artery stenosis may not be ideal
candidates for stenting and should be excluded by imaging (Abou-
Chebl, 2011). Furthermore, testing for effectiveness of platelet
aggregation inhibition and resistance of antiplatelet agents was
not investigated in these trials. The exact regimen of “best med-
ical therapy” has itself not been elucidated and requires further
investigation. Guidelines in antiplatelet therapy in coronary stent-
ing suggest that prolonged dual-therapy is associated with better
outcomes than monotherapy (Popma et al., 2004). Further ran-
domized controlled trials are required with appropriate selection
of patients most likely to beneﬁt from intracranial stenting over
medical therapy alone with appropriate antiplatelet regimens that
includes resistance testing.
CAROTID STENTING
Thromboembolus and stroke is the most common complication
associated with carotid stenting.
Rates of periprocedural stroke (within 30 days) were low in the
CREST trial (4.1%; Brott et al., 2010) when compared to the three
1http://members.asnr.org/misc/NINDS_Clinical_Alert.pdf
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other major carotid stenting trials: SPACE trial 6.8% (SPACE Col-
laborative Group et al., 2006), EVA-3S 9.6% (Mas et al., 2006),
but not ICSS 4.0% (ICSS Investigators, 2010). There were several
confounding factors to explain these differences, including vari-
able inclusion criteria for degrees of stenosis and clinical history of
stroke or TIA.Variability in antiplatelet regimens may also explain
some of the differences in stroke post procedure.
TheCREST trial pre-procedure loading involved 48 hof 325mg
aspirin twice daily and 75mg clopidogrel twice daily. When the
procedure was scheduled within 48 h a more rapid loading reg-
imen involved 650mg of aspirin and 450mg of clopidogrel at
least 4 h before the procedure. Post procedure regimens involved
dual-therapy for 4weeks with 75mg of clopidogrel and one or
two 325mg doses of aspirin daily. Single agent therapy was used
after 4 weeks. This regimen was more aggressive than other trials
that had higher rates of stroke. Rates of stroke were double that
of the CREST trial in the EVA-3S trial (9.6%). The dosing for
pre-procedure loading involved aspirin between 100 and 300mg
daily as well as clopidogrel 75mg daily for 3 days. The post proce-
dure regimen was similar. However antiplatelet compliance rates
in EVA-3S were poor. Seventeen percent of patients were not on
dual antiplatelet medications prior to procedure and 15% were
not compliant post procedure (Gupta et al., 2010). The SPACE
trial with rates of stroke at 6.8% had a similar regimen to the EVA-
3S trial: 100mg of aspirin daily and 75mg of clopidogrel daily for
3 days pre-procedure and at least 1month post procedure. Adher-
ences to the pre-procedure loading also varied between trials, with
97.7% adherence in CREST, vs. 82.9% in EVA-3S. No studies of
platelet function were pursued in these trials to assess effectiveness
of platelet inhibition prior to procedure. Variability amongst dos-
ing regimenmay in part explain differences in stroke rates between
trials.
A meta-analysis of 3433 patients from the EVA-3S, SPACE,
and ICSS trials published in The Lancet 2010 (Collaboration,
2010) reported that the greater morbidity related to stenting over
endarterectomy correlatedwith age. Patients over the age of 70 had
a signiﬁcantly higher risk of 30-day stroke with stenting compared
to endarterectomy (10.5 vs. 4.4%, P = 0.0078). Patients below
age of 70 did not have a signiﬁcant difference between groups
(5.1 vs. 4.5%). The study reported a linear increase of the risk
ratio between stenting and endarterectomy with age. The authors
concluded that a biological mechanism might be mediating the
association. General burden of atherosclerosis of the aortic arch,
increased plaque instability, altered conﬁguration of the aortic
arch, or vessel tortuosity were raised as possibilities. Intervention-
alist (compared to surgeon) experience has also been raised as a
signiﬁcant factor that may in part explain the disparity of rates
of stroke complication between the carotid stenting RCTs (Gupta
et al., 2010).
IMPLICATIONS FOR NEUROINTERVENTION PRACTICE
The WFITN2 has acknowledged the lack of consensus guidelines
for antiplatelet therapy in the periprocedural setting. Their website
recommendations were compiled from consensus expert opinion
2www.wﬁtn.org
in 2007 but have not been formally published. The recommenda-
tions were released in an effort to spark a debate over appropriate
guidelines. As yet, no such guidelines exist.
Pandya et al. (2010) recently reported the largest prospective
trial to evaluate pre-procedure dosing regimens and antiplatelet
resistance in neurointerventional procedures. Data was collected
from 216 consecutive patients including all neurointerventional
procedures. Thirteen percent of patients taking aspirin were found
to be resistant (>550 ARU) while 66% of patients taking clopi-
dogrel were resistant (<50% inhibition of P2Y12/ADP receptor).
Patients taking clopidogrel 75mg for≥7 days, 300mg for 24 h, and
600mg same day load had a mean P2Y12/ADP inhibition of 45%,
35% (P = 0.09), and 16%, respectively (P = 0.005). The authors
suggested this data may reﬂect an inferiority with same day load-
ing when compared to longer loading periods to achieve adequate
platelet inhibition.
Lee et al. (2008) applied point-of-care tests to assess antiplatelet
response prior to neurointerventional procedures. One-hundred
six consecutive patients were assessed in a single center from 2006
to 2007. Antiplatelet regimen included aspirin (325mg daily)
and clopidogrel (75mg for 5–10 days pre-procedure). Two per-
cent of patients demonstrated aspirin poor response (<550 ARU)
and 42.9% of patients demonstrated clopidogrel poor response
(>40% inhibition). Three cases were complicated by intrapro-
cedural thrombosis, with all three cases observed in the poor
responders group. The authors commented that frequency of poor
responders appears high in a population undergoing neurointer-
ventional procedures. Routinemonitoringwith point-of-care tests
may be helpful for early identiﬁcation of non-responders.
Prabhakaran et al. (2008) conducted a similar single center
prospective evaluation in 76 patients undergoing cerebrovascu-
lar stenting. Aspirin resistance was detected in 4.2% of patients
(ARU> 550) and clopidogrel resistance in 51.9% of patients
(>40% inhibition). Outcomes were not assessed in relation to
rates of resistance in this group. Interestingly, a signiﬁcant inverse
relationship was demonstrated between dose of aspirin and rate
of resistance, with lower weekly doses of aspirin correlating to
higher rates of resistance (r =−0.31,P = 0.01). The authors high-
lighted the need for further investigation of ideal dosing, timing
and duration of antiplatelet therapy for neurointerventional stent
procedures.
The existence of aspirin and clopidogrel resistance appears cer-
tain. Less clear is the true prevalence and appears dependent on
factors including choice of test, dose of antiplatelet agent, age of
patient, and presence of comorbidities including hypertension and
hyperlipidemia. The use of point-of-care tests such as the Veri-
fyNow RPFA and P2Y12 enable rapid testing and may assist in
clinical decision making but more data are needed for validation.
In assessing platelet function, the P2Y12 is well correlated to LTA,
which has been shown in large trials to be associated with loss-
of-function genetic CYP2C19 expression and signiﬁcantly poorer
cardiovascular outcomes in patients taking clopidogrel. It is likely,
but not yet tested, that similar associations with stroke will exist
in populations that undergo neurointerventional procedures. The
most signiﬁcant impact on future risk of ischemic event in poor
responders to clopidogrel was detected in patients with a history of
coronary stenting. Whether similar conclusions can be drawn for
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patients with intracranial or extracranial stents remains to be seen.
Use of point-of-care tests in patients undergoing carotid stenting
has been described (Maruyama et al., 2011), with addition of an
extra agent showing improved platelet aggregation inhibition.
A risk of thromboembolism exists in coiling procedures.
Stroke associated with coiling occurs in between 2 and 9% of
patients despite antiplatelet therapy, and may be as high as 25%
when considering silent ischemia on MRI diffusion restriction.
There is a suggestion that antiplatelet agents may reduce the
risk of thromboembolism without increasing the risk of hem-
orrhage, but this question needs to be studied in a prospective
trial. Risk of thromboembolism may increase with wide necked
aneurysms. The increased prevalence of antiplatelet resistance in
older populations that have increased comorbidities should be
taken into account when pursuing neurointerventional proce-
dures in this group. Poorer outcomes in carotid stenting may be
related to increased rates of antiplatelet resistance in this group
and requires further investigation. Point-of-care testing in these
groups may be warranted. Meta-analysis evidence provides sup-
port that higher doses of aspirin lead to lower levels of resistance.
This may be a treatment option in patients shown to have aspirin
resistance.
RECOMMENDATION
Effective antiplatelet therapy reduces complications associated
with neurointerventional procedures. Point-of-care tests to assess
response to aspirin and clopidogrel are available but require fur-
ther validation. Pre-procedure loading with antiplatelet agents
may be more effective over 7 days than more rapid regimens.
Titration of dosing or addition of second antiplatelet agent fol-
lowing diagnosis of resistance may be reasonable but has not been
prospectively investigated.
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